Chandekar KR - Search Results

1

Chandekar KR, Prashanth A, Vinjamuri S, Kumar R. Chandekar KR, et al. Diagnostics (Basel). 2023 Jun 9;13(12):2018. doi: 10.3390/diagnostics13122018. Diagnostics (Basel). 2023. PMID: 37370912 Free PMC article. Review.

2

Perirenal Fascia - an Uncommon Site of Metastases in Prostate Cancer Detected on ⁶⁸Ga-PSMA-11 PET/CT.

Chandekar KR, Satapathy S, Panaiyadiyan S, Kumar R. Chandekar KR, et al. Nucl Med Mol Imaging. 2023 Oct;57(5):254-255. doi: 10.1007/s13139-023-00801-w. Epub 2023 Apr 28. Nucl Med Mol Imaging. 2023. PMID: 37720882

3

Head-to-head comparison of [⁶⁸Ga]Ga-DOTA.SA.FAPi with [¹⁸F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers.

Ballal S, Yadav MP, Roesch F, Satapathy S, Moon ES, Martin M, Wakade N, Sheokand P, Tripathi M, Chandekar KR, Agarwal S, Sahoo RK, Rastogi S, Bal C. Ballal S, et al. Among authors: chandekar kr. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):233-244. doi: 10.1007/s00259-023-06404-z. Epub 2023 Aug 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37642703

4

Utility of ¹⁸F-FDG PET/CT in Assessment of Disease Extent and Response to Treatment in Xanthoma Disseminatum.

Chandekar KR, Satapathy S, Sharma A, Taneja N, Tripathi M, Bal C. Chandekar KR, et al. J Nucl Med Technol. 2023 Dec 5;51(4):335-336. doi: 10.2967/jnmt.123.266162. J Nucl Med Technol. 2023. PMID: 37699645

5

Orbital and brain metastases on ⁶⁸Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA therapy.

Parihar AS, Chandekar KR, Singh H, Sood A, Mittal BR. Parihar AS, et al. Among authors: chandekar kr. Asia Ocean J Nucl Med Biol. 2021 Winter;9(1):67-70. doi: 10.22038/AOJNMB.2020.50820.1347. Asia Ocean J Nucl Med Biol. 2021. PMID: 33392353 Free PMC article.

6

Molecular imaging as a tool for evaluation of COVID-19 sequelae - A review of literature.

Chandekar KR, Satapathy S, Singh H, Bhattacharya A. Chandekar KR, et al. World J Radiol. 2022 Jul 28;14(7):194-208. doi: 10.4329/wjr.v14.i7.194. World J Radiol. 2022. PMID: 36160629 Free PMC article. Review.

7

Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.

Chandekar KR, Satapathy S, Bal C. Chandekar KR, et al. Clin Endocrinol (Oxf). 2024 Feb;100(2):181-191. doi: 10.1111/cen.15001. Epub 2023 Dec 4. Clin Endocrinol (Oxf). 2024. PMID: 38050454

8

Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.

Satapathy S, Tupalli A, Chandekar KR, Ballal S, Bal C. Satapathy S, et al. Among authors: chandekar kr. Clin Endocrinol (Oxf). 2023 Nov;99(5):483-491. doi: 10.1111/cen.14950. Epub 2023 Jul 25. Clin Endocrinol (Oxf). 2023. PMID: 37491776

9

Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.

Chandekar KR, Singh H, Kumar R, Kumar S, Kakkar N, Mittal BR, Singh SK. Chandekar KR, et al. Clin Nucl Med. 2023 Jan 1;48(1):e1-e8. doi: 10.1097/RLU.0000000000004430. Epub 2022 Oct 14. Clin Nucl Med. 2023. PMID: 36240786

10

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.

Satapathy S, Chandekar KR, Bal C. Satapathy S, et al. Among authors: chandekar kr. PET Clin. 2023 Apr;18(2):215-221. doi: 10.1016/j.cpet.2022.11.004. PET Clin. 2023. PMID: 36858746 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page